Journal of Clinical Immunology

, Volume 37, Issue 4, pp 339–341 | Cite as

Placental Transfer of Canakinumab in a Patient with Muckle-Wells Syndrome

  • Makiko Egawa
  • Kohsuke Imai
  • Masaaki Mori
  • Naoyuki Miyasaka
  • Tetsuo KubotaEmail author
Letter to Editor

To the Editor:

Muckle-Wells syndrome (MWS) is a rare autoinflammatory condition caused by the overproduction of interleukin-1β (IL-1β). MWS is due to heterozygous mutations in NLRP3, the gene encoding cryopyrin, which regulates the production of IL-1β [1]. Systemic inflammation causes recurrent fever, urticarial rash, joint deformities, and sensorineural hearing loss of various severities. Canakinumab, a human anti-IL-1β monoclonal antibody that selectively blocks IL-1β, has been licensed for cryopyrin-associated periodic syndrome (CAPS) including MWS since 2011 in Japan, but there has been no report of its efficacy and safety during pregnancy. This case report describes the clinical course of a MWS patient administered canakinumab during pregnancy.

The patient was a 32-year-old Japanese woman in her first pregnancy. She had suffered from recurrent episodes of fever, conjunctivitis, headache, abdominal pain, arthritis, and urticarial rash since 3 years of age and had sensory hearing...


Muckle-Wells syndrome pregnancy canakinumab placental transfer 



The measurement of canakinumab concentration was performed by Novartis Pharma AG and Novartis Pharma K.K.

Authors’ Contributions

ME wrote the manuscript and KI, MM, and TK reviewed the manuscript, and all authors reviewed the manuscript and approved the final version.

Compliance with Ethical Standards

Written informed consent was obtained from the patient for continuous treatment with canakinumab during pregnancy, and for publication of this report.

Research Involving Human Participants

All procedures performed in the study were in accordance with the Helsinki principles.

Conflict of Interest

TK and ME have received speaking fees from Novartis. Tokyo Medical and Dental University (TMDU) has received unrestricted research grants for Department of Lifetime Clinical Immunology from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceuticals, Mitsubishi Tanabe Pharma Co., UCB Japan, CSL Behring, Towa Pharmaceutical Co., Ltd., Abbvie Japan Co., Ltd., Japan Blood Products Organization, Ayumi Pharmaceutical Co. and Nippon Kayaku Co., Ltd. MM has received lecture fees from MSD K.K. and AbbVie LLC and received consulting fees from Daiichi Sankyo Co., Ltd. and Taisho Pharmaceutical Co., Ltd. This work was supported by grants from the “Research on Measures for Intractable Diseases” Project: matching fund subsidy from the Japanese Ministry of Health, Labor, and Welfare.


  1. 1.
    Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29:301–5.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Koike R, Kubota T, Hara Y, Ito S, Suzuki K, Yanagisawa K, et al. A case of Muckle-Wells syndrome caused by a novel H312P mutation in NALP3 (cryopyrin). Mod Rheumatol. 2007;17:496–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Chang Z, Spong CY, Jesus AA, Davis MA, Plass N, Stone DL, et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes. Arthritis Rheumatol. 2014;11:3227–32.CrossRefGoogle Scholar
  4. 4.
    Levy RA, de Jesus GR, de Jesus NR, Klumb EM. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev. 2016;15:955–63.CrossRefPubMedGoogle Scholar
  5. 5.
    Youngstein T, Lane T, Rowczenio D, Ozdogan H, Ugurlu S, Hoffmann P, et al. Anti-interleukin-1 therapies and pregnancy outcome: an international cohort. Ann Rheum Dis. 2015;74(suppl 2):860.Google Scholar
  6. 6.
    D’Ippolito S, Tersigni C, Marana R, Di Nicuolo F, Gaglione R, Rossi ED, et al. Inflammosome in the human endometrium: further step in the evaluation of the “maternal side”. Fertil Steril. 2016;105:111–8.Google Scholar
  7. 7.
    Hashira S, Okitsu-Negishi S, Yoshino K. Placental transfer of IgG subclasses in a Japanese population. Pediatr Int. 2000;42:337–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Paccaud Y, Berthet G, Von Scheven-Gete A, Vaudaux B, Mivelaz Y, Hofer M, et al. Neonatal treatment of CINCA syndrome. Pediatr Rheumatol Online J. 2014;12:52.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Makiko Egawa
    • 1
  • Kohsuke Imai
    • 1
  • Masaaki Mori
    • 2
  • Naoyuki Miyasaka
    • 3
  • Tetsuo Kubota
    • 4
    Email author
  1. 1.Department of Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental SciencesTokyo Medical and Dental UniversityTokyoJapan
  2. 2.Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental SciencesTokyo Medical and Dental UniversityTokyoJapan
  3. 3.Department of Comprehensive Reproductive Medicine, Graduate School of Medical and Dental SciencesTokyo Medical and Dental UniversityTokyoJapan
  4. 4.Department of Microbiology and Immunology, Graduate School of Health Care SciencesTokyo Medical and Dental UniversityTokyoJapan

Personalised recommendations